Wendy Naimark
Chief Technology Officer Ripple Therapeutics
Seminars
Wednesday 9th December 2026
Intravitreal Complement Factor B Inhibition for Geographic Atrophy: RTC-4202, an Epidel®-Based Sustained-Release Implant Targeting Factor B
4:00 pm
- Explaining the innovative way the Epidel® prodrug technology delivers drugs without polymers or delivery systems
- Introducing the rationale for an intravitreal approach to delivering Factor B inhibition locally to the retina
- Reviewing nonclinical data from the RTC-4202 IVT program demonstrating sustained PK, PD, and tolerability
NEW SPEAKING COMPANY
